公开(公告)号：US20220380466A1

公开(公告)日：2022-12-01

申请号：US17829807

申请日：2022-06-01

Applicant: Genentech, Inc.

Inventor： Chi-Chung LI ,  Carol Elaine O'HEAR ,  Xi CHEN

IPC: C07K16/28 ,  A61P35/02

Abstract: The present invention relates to the treatment of subjects having B cell proliferative disorders (e.g., high grade B-cell lymphomas, as well as non-Hodgkin's lymphomas, such as diffuse large B-cell lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody.

公开(公告)号：US20220153842A1

公开(公告)日：2022-05-19

申请号：US17516979

申请日：2021-11-02

Applicant: Genentech, Inc.

Inventor： Chi-Chung LI ,  Carol Elaine O'HEAR ,  Stephen James SIMKO, III ,  Iris Tranthuyngan TO ,  Klara TOTPAL ,  Hong WANG ,  Michael C. WEI ,  Shen YIN ,  Brendan Christian BENDER ,  Xi CHEN ,  Yu-Waye CHU ,  Maria HRISTOPOULOS

IPC: C07K16/28 ,  C07K16/46 ,  A61K47/68 ,  A61P35/00

Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.